CME

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Overview

Author(s)/Faculty: Michael A. Postow, MD; Kathleen M. Madden, MSN, FNP
Source: Healio - Hematology/Oncology Education Lab
Type: LectureArticles/Items: 5
Release Date: 4/28/2017Expiration Date: 4/27/2018
Credit Type: CMENumber of Credits: 1
Cost: FreeProvider: Vindico Medical Education
Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed in 2017. The early detection of melanoma is imperative for optimal clinical outcomes, with 98% of early diagnosed patients in the United States surviving past 5 years. For patients who are diagnosed with melanoma that has reached the lymph nodes or has metastasized to distant organs, the 5-year survival rates drop drastically to 62% and 18%, respectively. The recent approval by the US Food and Drug Administration of several targeted and immunotherapies have provided significant outcomes benefits to patients with advanced melanoma. However, especially regarding immunotherapies, challenges are still being encountered in selecting patients for therapy, in integrating immunotherapies into treatment strategies, and in managing therapy-associated adverse events, resulting in suboptimal outcomes in this patient population. This CME symposium recorded during the 2017 HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting focuses on optimizing clinical outcomes in patients with advanced melanoma through expert discussion pertaining to patient selection, immunotherapy selection and integration into optimal treatment protocols, and best practices for the identification and management of adverse events.

CME Information

page 1 of 8